Nonmyeloablative conditioning with allogeneic hematopoietic cell
transplantation for the treatment of high risk acute lymphoblastic
by Ron Ram, Rainer Storb, Brenda M. Sandmaier, David G. Maloney,
Ann E. Woolfrey, Mary Evelyn D. Flowers, Michael B. Maris, Gina G. Laport,
Thomas R. Chauncey, Thoralf Lange, Amelia A. Langston, Barry E. Storer,
and George Earl Georges
Haematologica 2011 [Epub ahead of print]
Citation: Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey AE, Flowers ME,
Maris MB, Laport GG, Chauncey TR, Lange T, Langston AA, Storer BE, and Georges GE.
Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the
treatment of high risk acute lymphoblastic leukemia. Haematologica. 2011; 96:xxx
E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, www.haemato-
logica.org) publishes peer-reviewed papers across all areas of experimental and clinical
hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organiza-
tion, and serves the scientific community with strict adherence to the principles of open
access publishing (www.doaj.org). In addition, the journal makes every paper published
immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH)
free digital archive of biomedical and life sciences journal literature.
Official Organ of the European Hematology Association
Published by the Ferrata Storti Foundation, Pavia, Italy
Early Release Paper
Support Haematologica and Open Access Publishing by becoming a member of the European Hematology Association (EHA)
and enjoying the benefits of this membership, which include free participation in the online CME program
Copyright 2011 Ferrata Storti Foundation.
Published Ahead of Print on April 20, 2011, as doi:10.3324/haematol.2011.040261.
Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the
treatment of high risk acute lymphoblastic leukemia
Short title: Nonmyeloablative transplantation for ALL patients
Ron Ram,1 Rainer Storb,1,2 Brenda M. Sandmaier,1,2 David G. Maloney,1,2 Ann Woolfrey,1,2
Mary E. D. Flowers,1,2 Michael B. Maris, 3 Ginna G. Laport,4 Thomas R. Chauncey,2,5
Thoralf Lange,6 Amelia A. Langston, 7 Barry Storer, 1,2 and George E. Georges1,2
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2University of Washington
School of Medicine, Seattle, WA, USA; 3Rocky Mountain Cancer Center, Denver, CO, USA;
4Stanford University, Stanford, CA, USA; 5Veterans Affairs Puget Sound Health Care System,
Seattle, WA, USA; 6University of Leipzig, Leipzig, Germany, and 7Emory University, Atlanta,
The work was supported by grants from the National Institutes of Health, Bethesda, MD, USA
(grants P01CA018029, P01CA078902, and P30CA015704). RR was a recipient of a fellowship
award from the Davidoff Foundation.
George E. Georges, M.D., Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N,
D1-100; Seattle, WA 98109 USA. Phone: international +206.6676886.
Fax: international +206.6676124. E-mail: email@example.com
We thank the research nurses Michelle Bouvier and Hsien-Tzu Chen and data manager Gresford
Thomas for their invaluable help in this study; Helen Crawford, Bonnie Larson, and Sue
Carbonneau for manuscript preparation; and especially the patients and their families, the
transplantation teams, physicians, nurses, long-term follow-up team and support personnel for
their dedicated care of patients on this study.
Background. Allogeneic hematopoietic cell transplantation is a potentially curative treatment for
patients with acute lymphoblastic leukemia. However, the majority of older adults with acute
lymphoblastic leukemia are not candidates for myeloablative conditioning regimens. A
nonmyeloablative preparative regimen is a reasonable treatment option for this group. We sought
to determine the outcome of nonmyeloablative conditioning and allogeneic transplantation in
patients with high-risk acute lymphoblastic leukemia.
Design and Methods. Fifty-one patients, median age 56 years, underwent allogeneic
hematopoietic cell transplantation from sibling or unrelated donors after fludarabine and 2 Gray
total body irradiation. Twenty-five patients had Philadelphia chromosome-positive acute
lymphoblastic leukemia. Eighteen of these patients received post-grafting imatinib.
Results. With median follow-up of 43 months, the 3-year overall survival was 34%. The 3-year
relapse/progression and non-relapse mortality rates were 40% and 28%, respectively. The
cumulative incidences of grades II and III-IV acute graft-versus-host disease were 53% and 6%,
respectively. The cumulative incidence of chronic graft-versus-host disease was 44%.
Hematopoietic cell transplantation in first complete remission and post-grafting imatinib were
associated with improved survival, p=0.005 and 0.03, respectively. Three-year overall survival
for patients with Philadelphia-negative acute lymphoblastic leukemia in first remission and
beyond first remission were 52% and 8%, respectively. For patients with Philadelphia
chromosome-positive acute lymphoblastic leukemia in first remission who received post-grafting
imatinib, the 3-year overall survival was 62%; for the subgroup without evidence of minimal
residual disease at transplantation, the overall survival was 73%.
Conclusions. For patients with high-risk acute lymphoblastic leukemia in first complete
remission, nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation, with
post-grafting imatinib for Philadelphia chromosome-positive disease, can result in favorable
Trial Registration: Clinicaltrials.gov identifier: NCT0036738
Key words: acute lymphoblastic leukemia, Philadelphia chromosome-positive, allogeneic
hematopoietic cell transplantation, nonmyeloablative conditioning, imatinib
Allogeneic hematopoietic cell transplantation (HCT) with a myeloablative conditioning
regimen is an established potentially curative treatment for patients with high-risk acute
lymphoblastic leukemia (ALL).1,2 However, many older adults with ALL are not candidates for
high dose conditioning and HCT.3,4 The use of nonmyeloablative conditioning with fludarabine
and low dose total body irradiation (TBI) can substantially decrease the toxicity of the
preparative regimen and extends allogeneic HCT to older or medically infirm patients.5,6 This
approach relies primarily on potent graft-versus-leukemia effects to prevent relapse of the
disease. Other reduced intensity regimens have been reported by investigators for the treatment
of patients with ALL.3,7-9 However, relapse has remained a major problem following reduced
intensity conditioning regimens.
In recent years, the development of imatinib mesylate, and subsequently the newer tyrosine
kinase inhibitors (TKIs), dasatinib and nilotinib, combined with chemotherapy were very
effective for inducing disease remission in patients with Philadelphia chromosome positive (Ph+)
ALL.10-13 Imatinib therapy after allogeneic HCT was well tolerated and improved relapse-free
survival following myeloablative conditioning compared to historical controls not given imatinib
therapy after HCT.14 A recent report showed that patients with Ph+ ALL who received induction
chemotherapy with imatinib followed by myeloablative conditioning and allogeneic HCT for
Ph+ ALL in CR1 had superior overall survival compared to patients who did not undergo HCT.15
We report on the multicenter experience with allogeneic HCT following nonmyeloablative
conditioning with fludarabine and 2 Gray (Gy) TBI for patients with high-risk ALL. We identify
risk factors for disease relapse and mortality. We also describe the causes of non-relapse
mortality (NRM) and the toxicity and efficacy of post-HCT imatinib for patients with Ph+ ALL.
DESIGN AND METHODS
This analysis includes 51 consecutive patients with ALL who were prospectively enrolled
and received non-myeloablative conditioning followed by allogeneic HCT on sequential multi-
institutional protocols between February 1, 2000 and July 30, 2009. The protocols were
registered as National Cancer Institute clinical trials. Patients treated with post-grafting imatinib
were registered on NCT00036738. Other patients were enrolled in sequential protocols specific
for donor type and minor variations in planned duration of post-grafting immunosuppression.
Patients were treated at 6 centers with the Fred Hutchinson Cancer Research Center (FHCRC),
Seattle, WA, acting as the coordinating center. All patients signed informed consent forms
approved by the local institutional review boards.
Patients with related or unrelated donors (URD) were eligible for nonmyeloablative
conditioning if they were older than 55 or 50 years, respectively. Younger patients were eligible
if they had high risk ALL and co-morbid conditions that excluded them from myeloablative
conditioning or if they had disease relapse after a preceding myeloablative HCT. Adult high risk
ALL was defined as greater than first complete remission (CR1), or CR1 and at least one of the
following: (1) age > 35 years, (2) white blood cells (WBC) > 30,000/µL at diagnosis for B cell
ALL or WBC >100,000/µL at diagnosis for T cell ALL or (3) Ph+ ALL with t(9;22).2 Pediatric
high risk ALL was defined as >CR1, or CR1 and the addition one of the following: (1) failure to
achieve complete remission after induction phase; (2) t(9;22) or t(4;11) clonal abnormalities; and
(3) poor response to prednisone in T cell ALL with WBC > 100,000/µL.16
Patients referred for HCT in CR1 had a median of 3 cycles (range, 3-4) of various standard
induction/intensification chemotherapy regimens.17-19 Pre-transplant disease status was assessed
within 21 days before HCT. CR was defined according to standard morphologic criteria as
outlined in the International Working Group.20 For patients in CR, minimal residual disease
(MRD) was assessed by multiparametric flow cytometry (minimum 4-color, cut-off level to
establish MRD positivity ≥ 0.01%), karyotype analysis (G-banding) and fluorescence in situ
hybridization (FISH). Quantitative reverse transcriptase–polymerase chain reaction (RT-PCR) of
p210 and p190 BCR/ABL mRNA was not part of the MRD workup in all of the patients with Ph+
ALL; thus, PCR results were not included in assessment of MRD. All patients and donors had
high resolution HLA-allele level typing performed for 10 HLA alleles (HLA-A, B, C, DRB1 and
DQB1). Patients received grafts from the following donors: HLA identical sibling (n=9), 10/10
HLA-allele matched URD (n=31), single HLA allele mismatched URD (n=6) and single HLA-
antigen mismatched URD (n=5). Pretransplant comorbidities were assessed retrospectively,
using the HCT comorbidity index (HCT-CI).21
Regimen and treatment plan
The conditioning regimen consisted of fludarabine (30 mg/m2/day on days -4 through -2
before HCT and 2 Gray (Gy) TBI given at 0.07 to 0.1 Gy/min from linear accelerator sources on
day 0.6 Patients received unmanipulated G-CSF mobilized peripheral blood stem cells (PBSC)
shortly after TBI. One patient received an unrelated bone marrow graft instead of PBSC. Post-
grafting immunosuppression consisted of combined mycophenolate mofetil and a calcineurin
inhibitor, cyclosporine or tacrolimus, as previously described.5,22-25
All patients received intrathecal methotrexate (12 mg/dose or 6 mg/dose if given via
Ommaya reservoir) for central nervous system (CNS) prophylaxis, two doses pre-transplant
(once per week) and six doses post-transplant (starting at day +30, once every 2 weeks). All men
received 16 Gy in 8 fractions of testicular irradiation during conditioning. All patients with a
history of CNS disease, 3 with Ph– and 4 with Ph+ ALL, received cranio-spinal irradiation as
part of the conditioning regimen.
The mean infused PBSC dose was 8.5×106 CD34/kg cells (range, 0.9-24.4). Engraftment
and donor chimerism were measured by variable number tandem repeat (VNTR) of
microsatellite markers at days 28, 56 and 84 after HCT.
Acute and chronic graft-versus-host disease (GVHD) were assessed as described.6,26
Toxicities occurring within the first 100 days were scored using the Common Terminology
Criteria for Adverse Events v3.0. Disease response after HCT was monitored with standard
marrow morphology, flow cytometry and conventional cytogenetics, FISH and, if indicated,
PCR for BCR-ABL transcripts.27 Disease responses were assessed at 1, 3, 6, 12 and 24 months
after HCT and/or as clinically indicated.
Ph+ ALL patients
Twenty-five patients had the Ph+ cytogenetic abnormality detected at diagnosis. After the
introduction of imatinib, 18 patients enrolled in a study evaluating the safety and efficacy of
incorporating post-grafting imatinib to the treatment regimen. Patients were initiated on imatinib
at a dose of 600 mg orally once daily either by their referring physician or at the transplant center
before enrollment on the study. Imatinib was stopped on day –2 before HCT to avoid interaction
with engraftment of donor hematopoietic cells. Imatinib was reinitiated at 400-600 mg daily after
HCT when ANC was >500/µL or on day +15 if there was no neutropenia. Imatinib was
continued for at least one year after HCT, unless there was toxicity or disease progression; all
patients received at least 1 month of imatinib. Dose reduction of imatinib was allowed for
mitigation of side effects/ toxicities.
Causes of death
In patients who relapsed or progressed with ALL, relapse/progression was listed as the primary
cause of death regardless of other associated events. Relapse was defined as recurrence of
malignancy based on one or more of the following parameters: marrow morphology, flow
cytometry, cytogenetic studies, including FISH, or RT-PCR for BCR/ABL transcripts. All deaths
occurring in the absence of relapse/progression were considered NRM.
Data were analyzed as of October 1, 2010. Overall survival (OS) was estimated using the
Kaplan-Meier method. Cumulative incidence estimates were calculated for acute and chronic
GVHD, relapse and NRM. Death was treated as a competing risk in the analyses of
relapse/progression and acute and chronic GVHD. Relapse/progression was treated as a
competing risk when analyzing NRM. Cox regression was used for univariate analyses of risk
factors for all time-to-event end points. For each analysis, hazard ratios (HR) and 95%
confidence intervals (95% CI) are given together with p values for comparisons with the
reference category. All p values are derived from likelihood ratio statistics and are two sided.
Fifty one patients underwent allogeneic HCT. All had high risk ALL including 19 who were
beyond CR1. Six patients were under 18 years of age (1 CR1 and 5 >CR1). Table 1 summarizes
the patients' characteristics. Twenty-five patients had Ph+ ALL. Of these, 18 received post-
grafting imatinib (Table 2). The median follow-up for surviving patients was 43 (range, 14-98)
Fifty patients achieved sustained donor engraftment. One patient with Ph+ ALL had non-
fatal primary graft rejection. This patient received an HLA matched unrelated marrow graft with
a 0.9×106/kg CD34+ cell dose. After graft rejection, this patient was treated with imatinib, chose
not to undergo a second HCT, relapsed and died 20 months after HCT. The median donor CD3+
T-cell chimerism levels for the 50 PBSC recipients at day 28 and day 84 were 79 (range, 15-
100)% and 88 (range, 48-100)%, respectively. The chimerism and engraftment patterns were not
different in patients treated with imatinib.
By day 120 after HCT, 53% of patients developed grade II acute GVHD and 6% developed
grades III-IV acute GVHD (Figure 1A). Among the patients who received HLA-identical sibling,
HLA-allele-matched unrelated donor, and HLA-allele/antigen mismatched unrelated grafts, the
overall incidences of grade II-IV acute GVHD were 33%, 50% and 91%, respectively.
Cumulative incidence of chronic extensive GVHD at 3 years was 42% (Figure 1B).
Among the patients with Ph+ ALL treated with post-grafting imatinib (n=18), 10 (56%)
developed grade II-IV acute GVHD. There was no significant difference between the incidences
of acute GVHD among patients who received or did not receive imatinib (HR=0.65, 95% CI 0.3-
1.4, p=0.25). Ten of the 18 patients (56%) developed chronic extensive GVHD and 5 (28%)
developed limited chronic GVHD. There was no significant difference in the incidence of
chronic GVHD among patients who received or did not receive imatinib (HR=1.4, 95% CI 0.6-
3.3, p=0.45). Five patients (36%) developed chronic skin GVHD while receiving imatinib
treatment. Discontinuation of imatinib after HCT was not associated with new onset or
exacerbation of chronic GVHD.
NRM at 3 years after HCT among all patients was 28% (Figure 1C). The following causes
were included under NRM: GVHD (n=4), GVHD-associated infections (n=8), sepsis (n=1),
congestive heart failure (n=1) and suicide (n=1). There was no significant difference in NRM
among patients who were or were not treated with post-HCT imatinib (HR=0.5, 95% CI 0.2-1.5,
p=0.20), respectively. The four deaths in the imatinib group were due to GVHD-associated
infections: bacterial pneumonia, sepsis with pancreatitis, respiratory syncytial virus pneumonia
and community acquired H1N1 viral pneumonia.
Disease relapse/ progression
Among the 51 patients, 22 (43%) had relapse/progression at a median of 5 (range, 0.3 to 58)
months after HCT. None of the patients developed isolated CNS relapse. None were treated with
donor lymphocyte infusion for disease relapse. The median time from the diagnosis of relapse to
death was 4 (range, 0.3-15) months in the 20 patients that had died at the time of analysis.
Overall, the 3-year estimated probability of relapse/progression was 40%. Univariate
analysis identified risk factors for relapse/progression (Table 3). Patients >CR1 at the time of
HCT had a significantly increased risk for relapse after HCT compared to those in CR1 (HR=3.9,
95% CI 1.6-9.5, p=0.002). For Ph– ALL (n=26), the 3-year estimated relapse rate for CR1 and
>CR1 patients was 15% and 62%, respectively (Figure 2). For Ph+ ALL (n=25), the 3-year
estimated relapse rate for CR1 and >CR1 was 32% and 67%, respectively (Figure 2). Two
patients with molecular evidence of disease after transplant were included as disease relapse. For
patients with Ph+ ALL, evidence of additional cytogenetic abnormalities at diagnosis was
borderline associated with an increased risk of relapse after HCT (HR=3.4, 95% CI 0.9-13,
The estimated 3-year OS among the 51 patients was 34%. Relapse was the primary cause of
death (n=20, 57% of all deaths). Univariate analysis performed for the entire cohort identified
>CR1 disease status as the only significant factor associated with increased mortality (HR=2.7,
95% CI 1.4-5.3, p=0.005), Table 3. Other factors (donor source, acute or chronic GVHD) were
not significantly associated with increased mortality. The 3-year OS for patients with Ph– ALL
in CR1 and >CR1 were 52% and 8%, respectively, (HR=3.4, 95% CI 1.3-9.1, p=0.01) (Figure
3A). Excluding the six pediatric patients, the 3-year OS for CR1 and >CR1 were 48% and 0%,
respectively (HR=4.5, 95% CI 1.4-15.1, p=0.01).
Among patients with Ph+ ALL, treatment with post-HCT imatinib was associated with
significantly decreased mortality (HR=0.3, 95% CI 0.1-0.9, p=0.03), Table 3. The 3-year OS for
patients with Ph+ ALL who were in CR1 vs. >CR1 were 47% and 17%, respectively; however,
this difference did not reach statistical significance (HR=1.8, 95% CI 0.6-5.4, p=0.32). For
patients in CR1 who received post-grafting imatinib, 3-year OS was 62% (Figure 3B, Table 2);
for the subgroup that had no evidence of MRD at HCT, the OS was 73%. Additional cytogenetic
abnormalities (beyond Ph+) detected at diagnosis, showed a trend for increased mortality
(HR=2.0, 95% CI 0.7-5.5, p=0.19).
Outcomes of patients age <18 years
Six patients with Ph– ALL were younger than 18 years at the time of HCT with a median
age of 11 (range, 8-16) years (4 had relapsed after a prior allograft, 1 CR1 and 1 CR3). Two
patients received HLA-antigen mismatched unrelated grafts. All 5 patients >CR1 relapsed (3 of
them within 6 months). All patients developed acute GVHD. The single CR1 patient is currently
alive at 88 months post HCT.
Outcomes of patients age >60 years
Sixteen patients (31%) were older than 60 years at the time of HCT with a median age of 63
(range, 61-69) years. Six of the 16 (38%) died from non-relapse causes and 4 (25%) had disease
relapse. Of the 9 patients with Ph– ALL, 2 in CR1 are currently alive for >2.1 years. Among
patients with Ph+ ALL (n=7), the estimated 3-year OS was 57%.
The median duration of post-HCT imatinib treatment was 11.5 (range, 3-50) months (Table
2). The drug was given at a daily dose range of 200-600 mg. In three patients dose modifications
were made. In general, imatinib was well tolerated. Three patients (17%) discontinued imatinib
because of adverse events, and all events were reversible (two gastrointestinal toxicities and one
recurrent pleural effusion).
Despite improvements in therapy, mortality from high-risk ALL has not substantially
decreased in older patients. Two large prospective trials and meta-analyses summarizing the
results of the previous controlled trials showed that allogeneic HCT after myeloablative
conditioning improved the outcome of adult patients with high risk ALL.2,28-31 However, in
patients with high risk disease, survival advantage was demonstrated only up to age 35 years.2,32
Developing HCT approaches for older or medically infirm patients with ALL has remained
challenging. While the outcome for patients not undergoing allogeneic HCT is very poor, those
who proceed with myeloablative conditioning followed by HCT have an unacceptably high
NRM.2,33 This multicenter study addressed the problem of NRM in older and medically infirm
patients by using a nonmyeloablative conditioning regimen consisting of fludarabine and 2 Gy
TBI which depended on allogeneic graft-vs.-leukemia effects for cure of high risk ALL.
We observed that OS was significantly improved for patients who underwent HCT early in
the course of their disease. For Ph– ALL patients in CR1, 3-year OS was 52%, while for patients
beyond CR1, 3-year OS was only 8%, primarily due to increased disease relapse. Other
investigators using various reduced intensity regimens and allogeneic HCT have reported 2 to 3-
year OS ranging from 20%-61%.3,7-9,34 The heterogeneous study outcomes might have been due
to differences in disease status and HCT donor characteristics. The positive impact of early
allogeneic HCT in CR1 was reported by Mohty et al. and Bachanova et al.3,7 Our study confirms
both this finding and the poor OS for patients beyond CR1. Furthermore, the sustained survival
plateau among CR1 patients demonstrates that durable long term disease free survival may be
achieved for a majority of Ph+ ALL patients treated with imatinib as well as for Ph– ALL
patients. Thus, in patients for whom allogeneic HCT is considered as post-remission therapy, it
should be recommended early rather than late in the course of the disease.
The most striking finding of our study was the favorable OS of 47% at 3 years for CR1 Ph+
patients given imatinib after HCT. The OS was 73% for those Ph+ patients in CR1 without MRD
at HCT. Relapse was increased in Ph+ patients with (a) additional cytogenetic abnormalities, (b)
those beyond CR1, and (c) among CR1 patients, those with MRD at HCT. The latter two factors
were not statistically significant probably because of the inclusion of patients before the
availability of imatinib. Age did not appear to limit the feasibility of our treatment protocol. For
example, Ph+ ALL patients older than 60 years had a 3-year OS of 57%. Incorporation of
imatinib and newer TKIs into the various phases of the treatment for Ph+ ALL patients has
reshaped the therapeutic algorithm. Thomas et al. showed that the incorporation of imatinib to
induction chemotherapy resulted in a 2-year OS of 56%, which included patients who proceeded
to myeloablative allogeneic HCT.35,36 A single center study showed that incorporation of
imatinib to induction chemotherapy with subsequent myeloablative conditioning and allogeneic
HCT resulted in 3-year OS of 78%.37 Currently, data for patients treated with TKIs and not
proceeding to allogeneic HCT are scarce. A recent phase II trial showed a 2-year estimated OS
of 64% for patients receiving only dasatinib in addition to induction and maintenance
chemotherapy.38 While these results are encouraging, a median follow-up of 14 months in this
cohort is probably too short to recommend alternative approaches to allogeneic HCT. Thus, it is
possible that the major role of TKIs, both in the medically “fit” and in the medically infirm or
older patients, is to allow a greater proportion of patients to receive allogeneic HCT.
Consequently, particularly in the setting of nonmyeloablative HCT, post-transplant TKIs appear
to provide a sufficient level of disease control until the development of a graft-vs.-leukemia
effect. In accordance with published data for imatinib after myeloablative HCT14, we showed
that imatinib was safe in the context of nonmyeloablative allogeneic HCT and was generally well
tolerated. In contrast to recent publications that suggested a role for imatinib in the prevention
and treatment of chronic skin GVHD39,40, we did not observe a significant decrease in the
incidence of chronic GVHD, nor detect an increase in the incidence of chronic GVHD after the
discontinuation of imatinib, although the number of patients in our study was limited. The
optimal duration of post-HCT imatinib therapy is unknown. In our study, patients were treated
with imatinib for varying time periods, according to physician and patient preferences. Two
patients were successfully treated with a second generation TKI after detection of molecular
relapse. Although the follow-up for these two patients was limited, these findings suggest that
close follow-up of patients is necessary and that molecular CR can be achieved after detection of
molecular relapse. Until data from larger cohorts are available, we would cautiously recommend
continuing indefinite treatment with TKI until there was evidence of either toxicity or disease
Although the incidence of acute GVHD was high, most cases were grade II and only 6% of
patients developed grades III-IV acute GVHD. In accordance with previous publications, the
highest incidence of acute GVHD occurred in patients receiving HLA-mismatched grafts.24 In
contrast to a previous study, we did not observe an inverse correlation between chronic GVHD
and relapse.41 In part, this could be explained by the fact that relapse in our cohort occurred early
after HCT (median, 5 months) particularly for patients with disease >CR1 Since ALL is
relatively rare in adults, our study was limited by the relatively small number of patients and that
enrollment occurred over a nearly 10-year period. Nonetheless, we showed that
nonmyeloablative conditioning and allogeneic HCT is a very feasible and effective treatment
option for high risk ALL patients in CR1. For Ph+ ALL patients in CR1, imatinib should be
given after HCT since it appears to improve OS. Our results suggest that non-myeloablative
conditioning and allogeneic HCT is a potentially curative treatment option for older or medically
infirm patients with high risk ALL in CR1. For patients beyond CR1, post-HCT maintenance
with novel agents should be explored and studies addressing the role of next generation TKIs
given after HCT are warranted.
GEG, RFS, BMS, DGM, MM provided conception and design of the study; RFS provided
administrative support; BMS, AW, MM, RL, TC, TL, AL, MEDF provided study materials or
patients; RR, GEG, BS, BMS, DGM, MEDF, MM, GGL, TC, TL, AL were responsible for the
collection and assembly of data; RR, GEG, BS, RFS, BMS provided data analysis and
interpretation; RR, GEG, RFS, BMS, MEDF wrote the manuscript; all authors gave their
approval for the final version of the manuscript. The authors reported no potential conflicts of
1. Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, et al. Long-
term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after
allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year
experience with the fractionated total body irradiation-etoposide regimen. Blood
2. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In
adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved
from a matched sibling allogeneic transplantation in first complete remission, and an
autologous transplantation is less effective than conventional consolidation/maintenance
chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL
XII/ECOG E2993). Blood 2008;111(4):1827-33.
3. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, et al. Reduced
intensity conditioning allogeneic stem cell transplantation for adult patients with acute
lymphoblastic leukemia: a retrospective study from the European Group for Blood and
Marrow Transplantation. Haematologica 2008;93(2):303-6.
4. Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML?
Best Practice & Research Clinical Haematology 2007;20(1):85-90.
5. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et
al. Hematopoietic cell transplantation in older patients with hematologic malignancies:
replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood
6. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, et al. HLA-
matched unrelated donor hematopoietic cell transplantation after nonmyeloablative
conditioning for patients with hematologic malignancies. Blood 2003;102(6):2021-30.
7. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in
adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord
blood or sibling donor transplantation. Blood 2009;113(13):2902-5.
8. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernandez-Aviles F, et al.
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in
acute lymphoblastic leukemia: a feasibility study. Haematologica 2003;88(5):555-60.
9. Shimoni A, Rand A, Hardan I, Shem-Tov N, Stanevsky A, Yerushalmi R, et al. Allogeneic
hematopoietic stem-cell transplantation in adult acute lymphoblastic leukemia: Better
outcome in transplantation during first complete remission and with myeloablative
conditioning [abstract]. Blood. 2008;112(11):1131-32, #3295.
10. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete
remission rate and promising outcome by combination of imatinib and chemotherapy for
newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the
Japan Adult Leukemia Study Group. J Clin Oncol 2006;24(3):460-6.
11. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, et al. Imatinib
combined with induction or consolidation chemotherapy in patients with de novo
Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-
2003 study. Blood 2007;109(4):1408-13.
12. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al.
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with
Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or
intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110(7):2309-15.
13. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in
imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med
14. Carpenter PA, Snyder DS, Flowers MED, Sanders JE, Gooley T, Martin PJ, et al.
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-
risk Philadelphia chromosome-positive leukemia. Blood 2007;109(7):2791-3.
15. Hatta Y, Mizuta S, Ohtake S, Sugiura I, Ueda Y, Kanamori H, et al. Promising outcome of
imatinib-combined chemotherapy followed by allogeneic hematopoietic stem cell
transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia:
Results of the Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 Regimen
[abstract]. Blood. 2009;114(22):1201-2, #3090.
16. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, et al.
Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute
lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation
in an international prospective study. Lancet 2005;366(9486):635-42.
17. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up
results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and
dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic
leukemia. Cancer 2004;101(12):2788-801.
18. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, et al. A five-drug
remission induction regimen with intensive consolidation for adults with acute
lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood
19. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy
for adult acute lymphoblastic leukemia. J Clin Oncol 2002;20(10):2464-71.
20. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised
recommendations of the International Working Group for Diagnosis, Standardization of
Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in
Acute Myeloid Leukemia. J Clin Oncol 2003;21(24):4642-9.
21. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, et al.
Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status
are independent predictors of morbidity and mortality after allogeneic nonmyeloablative
hematopoietic cell transplantation. Cancer 2008;112:1992-2001.
22. Burroughs L, Mielcarek M, Leisenring W, Sandmaier BM, Maloney DG, Baron F, et al.
Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease
after nonmyeloablative hematopoietic cell transplantation. Transplantation 2006;81(6):818-
23. Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT, et al.
Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and
unrelated donor hematopoietic cell transplantation. Blood 2005;106(13):4381-8.
24. Nakamae H, Storer BE, Storb R, Storek J, Chauncey TR, Pulsipher MA, et al. Low-dose
total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem
cell transplantation and immunologic recovery in patients with hematologic malignancies:
a multicenter trial. Biol Blood Marrow Transplant 2010;16(3):384-94.
25. Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, et al. Unrelated
donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell
transplantation after nonmyeloablative conditioning: the effect of postgrafting
mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006;12:454-65.
26. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J, et al. 1994
Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15(6):825-
27. Cazzaniga G, d'Aniello E, Corral L, Biondi A. Results of minimal residual disease (MRD)
evaluation and MRD-based treatment stratification in childhood ALL.(Review). Bailliere's
Best Practice in Clinical Haematology 2002;15(4):623-38.
28. Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC,
et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients
with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus
no-donor comparison. Blood 2009;113(6):1375-82.
29. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, et al.
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-
positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation
over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC
UKALLXII/ECOG2993. Blood 2009;113(19):4489-96.
30. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell
transplantation as part of postremission therapy improves survival for adult patients with
high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006;106(12):2657-63.
31. Ram R, Gafter-Gvili A, Vidal L, Paul M, Ben-Bassat I, Shpilberg O, et al. Management of
adult patients with acute lymphoblastic leukemia in first complete remission: systematic
review and meta-analysis. Cancer; prepublished online April 27, 2010; doi:
32. Goldstone AH, Rowe JM. Transplantation in adult ALL. Hematology 2009: American
Society of Hematology Education Program Book 2009;593-601.
33. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute
lymphoblastic leukemia from the 1980s to the early 21st century. Blood 2009;113(7):1408-
34. Stein AS, Palmer JM, O'Donnell MR, Kogut NM, Spielberger RT, Slovak ML, et al.
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for
adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant
35. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Treatment of
Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and
imatinib mesylate. Blood 2004;103(12):4396-407.
36. Thomas DA, Kantarjian HM, Ravandi F, Faderl S, Garcia-Manero G, Wierda W, et al.
Long-term follow-up after frontline therapy with the hyper-CVAD and imatinib mesylate
regimen in adults with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL)
[abstract]. Blood. 2007;110(11):10a-11a, #9.
37. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, et al. The effect of first-line
imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults
with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
38. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, et al. First report of phase II
study of dasatinib with hyperCVAD for the frontline treatment of patients with
Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood;
prepublished online May 13, 2010; doi:10.1182/blood-2009-12-261586.
39. Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L, et al. Imatinib
mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.
40. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, et al. Imatinib for
refractory chronic graft-versus-host disease with fibrotic features. Blood 2009;114(3):709-
41. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, et al. Graft-
versus-tumor effects after allogeneic hematopoietic cell transplantation with
nonmyeloablative conditioning. J Clin Oncol 2005;23(9):1993-2003.
Table 1 Characteristics of ALL patients, disease and transplantation.
Characteristics Ph– ALL (n=26) Ph+ ALL (n=25)
Median age: years (range) 56 (8-65) 57 (38-69)
Disease status at time of HCT: n, (%)
CR1 w/o MRD 12 (46%) 13 (52%)
CR1 with MRD 1 (4%) 6 (24%)
>CR1 (CR2/CR3) 13 (50%) 5 (20%)
Persistent disease 0 1 (4%)
Months from diagnosis to HCT: median, (range)
CR1 7.7 (4-10.7) 7.6 (4.4-10.9)
>CR1 30.6 (10.7-90.7) 38.7 (8.9-126.1)
History of myeloablative HCT (%)
4 (15%) 2 (8%)
0-1 9/17 (53%) 14/18 (78%)
≥2 8/17 (47%) 4/18 (22%)
Recipient gender (male/female) 11/15 16/9
Female donor to male recipient: (%) 5 (19%) 6 (24%)
Donor type: (%)
HLA-identical sibling 4 (15%) 5 (20%)
Unrelated HLA matched 14 (54%) 17 (68%)
1 HLA allele mismatched 3 (12%) 3 (12%)
Cell dose × 106 CD34+ cells/kg: median, (range)
1 HLA antigen mismatched 5 (19%) 0
8.8 (2-20.2) 8.2 (0.9-24.4)
Cell source (marrow/PBSC) 0/26 1/25
ALL: acute lymphoblastic leukemia, CR1: first complete remission, HCT-CI: hematopoietic
cell transplantation comorbidity index, MRD: minimal residual disease, PBSC: peripheral blood
stem cells, Ph: Philadelphia chromosome. 1Data were available for 17 Ph– ALL patients and for
18 Ph+ ALL patients.
Table 2 Characteristics of Ph+ ALL patients treated with imatinib after HCT.
status at last
1 6 HyperCVAD no CR1 no 11 no n/a dead Rel 13
2 9 HyperCVAD no CR1 yes- FCM 8 yes n/a dead NRM 28
3 6 Larson no CR1 no 50 yes n/a alive CR 73
4 7 HyperCVAD yes CR1 no 11 yes n/a dead NRM 12
5 5 HyperCVAD no CR1 no 24 yes no alive CR 77
6 5 HyperCVAD yes CR1 no 6 yes n/a dead Rel 8
7 10 GMALL yes CR1 no 4 yes n/a alive CR 90
8 4 HyperCVAD no CR1 no 24 no no alive PCR Relapse
9 8 HyperCVAD no CR1 no 45 yes n/a alive CR 62
10 9 HyperCVAD yes CR1 yes-FCM 3 yes n/a dead Rel 5
11 5 HyperCVAD yes CR1 no 18 yes n/a alive CR 33
12 9 Linker no CR1 no 12 no yes alive CR 39
13 8 HyperCVAD yes CR1 no 3 no yes alive CR 32
14 82 HyperCVAD,
yes CR2 yes-FCM 14 yes n/a alive PCR Relapse
– CR on
15 12 HyperCVAD no CR2 yes-FISH 10 yes n/a dead NRM 10
16 11 HyperCVAD,
yes CR2 yes-FCM 16 no no dead Rel 16
17 91 SWOG 9400,
yes CR3 no 6 yes n/a dead NRM 7
18 10 HyperCVAD no Relapse yes-Histo 14 yes n/a dead Rel 14
disease relapse after HCT. Two patients (UPN 8 and 14) had disease relapse after HCT detected by PCR and flow cytometry and are currently
alive in molecular CR. UPN 8 discontinued imatinib at 24 months after HCT, had disease relapse detected by PCR for the BCR/ABL p190
transcript at 43 months. This patient was retreated with imatinib, achieved a molecular CR within 2 months and remained PCR negative for 12
months. At 57 months after HCT, molecular relapse was again detected by BCR/ABL p190 transcript and flow cytometry of the bone marrow with
0.35% aberrant blasts, and therapy was changed to dasatinib. Molecular CR was achieved within 1 month and the patient has remained in
molecular CR for 5 months. UPN14 had molecular relapse detected by PCR BCR/ABL p190 transcript and flow cytometry 0.002% at 17 months
after HCT. This patient was treated with nilotinib, achieved a molecular CR within 2 months and has remained in molecular CR for 8 months.
Additional cytogenetic abnormalities at any time prior to allogeneic HCT: UPN4: complex (+7, +8, -11, -12, der 19), UPN6: complex (+2,
+5,+10,+16,+18,+19,+21,+X), UPN7:, t(9;14), UPN10: (+8,+22),UPN11:(-7), UPN13:(-7), UPN14: complex(+2, -9,-11,-Y, inv7p13, +13p11),
UPN16: complex (+5,+8,+8,+13,+14,+20), UPN17: complex (-7,-8,-13,-16,+11). 12 patients were initiated/maintained on imatinib 600 mg daily,
6 patients were initiated/maintained on imatinib 400 mg daily (UPN 9, 11, 12, 13,16, 17).UPN 2, 5 and 12 had subsequent imatinib dose reduction
to 200-400 mg daily. Ph+ ALL: Philadelphia chromosome positive acute lymphoblastic leukemia; HCT: hematopoietic cell transplantation; Dx:
diagnosis; MRD: minimal residual disease; CNS: central nervous system; GVHD: graft vs. host disease; HyperCVAD: hyper fractionated
cyclophosphamide, vincristine, doxorubicin and dexamethasone; GMALL: German multicenter ALL regimen; MEI: mitoxantrone, etoposide,
ifosfamide; DA: daunorubicin, ara-c; HIDAC: high dose ara-c; CR: complete remission; FISH: fluorescent in situ hybridization; FCM: flow
cytometry; Histo: conventional histology. n/a: not applicable.
All patients except UPN 10 had imatinib therapy prior to HCT. UPN 16 had CNS disease prior to HCT. None of the patients had CNS
Table 3. Prognostic factors for relapse and mortality using univariate analysis.
HR (95% CI) p HR (95% CI) p
Entire cohort (n=51)
>CR1 3.9 (1.6-9.5) 0.002 2.7 (1.4-5.3) 0.005
Matched URD (vs. sibling) 1.1 (0.3-3.9) 0.86 0.6 (0.2-1.3) 0.16
Acute GVHD1 0.5 (0.2-1.2) 0.11 0.9 (0.4-1.7) 0.69
Chronic GVHD1 0.7 (0.2-2.3) 0.53 1.0 (0.5-2.2) 0.98
Ph+ ALL (n=26)
>CR1 2.4 (0.7-8.6) 0.20 1.8 (0.6-5.4) 0.32
Additional cytogenetic abnormalities 3.4 (0.9-13) 0.06 2.0 (0.7-5.5) 0.19
Treatment with imatinib 0.4 (0.1-1.5) 0.20 0.3 (0.1-0.9) 0.03
ALL: acute lymphoblastic leukemia, CI: confidence interval, >CR1: disease stage greater than
first complete remission, GVHD: graft-vs.-host disease, HR: hazard ratio, Ph: Philadelphia
chromosome, URD: unrelated donor. 1Analyzed as a time-dependent covariate.
Figure 1. Cumulative incidences (n=51) of (A) Acute graft-vs.-host disease (GVHD): 53% grade
II, 6% grade III-IV; (B) Chronic extensive GVHD: 42% incidence at 3 years; (C) Non-relapse
mortality, 28% incidence at 3 years.
Figure 2. Cumulative relapse rate for Ph– ALL CR1 (n=13) vs. >CR1 (n=13) and Ph+ ALL CR1
(n=19) vs. >CR1 (n=6). Molecular disease relapse (PCR or flow cytometry positive) without
morphologic evidence of disease was included as relapse.
Figure 3. Overall survival for (A) Ph– ALL CR1 (n=13) vs. >CR1 (n=13) and (B) Ph+ ALL
patients receiving imatinib after hematopoietic cell transplantation, CR1 (n=13) vs. >CR1 (n=5).
DOI: 10.3324/haematol.2011.040261 Download full-text